Semaglutide Weight Loss Results
Semaglutide weight loss averages 15% of body weight in clinical trials. See timeline data, realistic expectations, and factors that influence results.
STEP 1 avg. loss
14.9% at 68 weeks
Lost >= 10%
69.1% of patients
Lost >= 20%
32.0% of patients
Real-world avg.
10-13% at 12 months
Peak loss period
Months 3-9
Clinical Trial Results
The STEP (Semaglutide Treatment Effect in People with Obesity) program provides the most robust data on semaglutide for weight loss. STEP 1 enrolled 1,961 adults with BMI >= 30 (or >= 27 with comorbidities) and demonstrated a mean weight loss of 14.9% at 68 weeks with Wegovy 2.4mg vs. 2.4% with placebo.
Breakdown by response: 86.4% lost at least 5% body weight, 69.1% lost at least 10%, 50.5% lost at least 15%, and 32.0% lost at least 20%. These results represent the most effective FDA-approved weight loss medication at the time of the trial.
Weight Loss Timeline
Weight loss with semaglutide follows a predictable pattern. During the first 4-8 weeks (titration phase), weight loss is modest at 1-3% as doses are low. From months 2-6, weight loss accelerates significantly as patients reach therapeutic doses. The steepest weight loss curve occurs between months 3-9. By months 9-15, the rate of loss typically slows and patients approach a plateau around 12-18 months.
The STEP 1 trial showed that approximately two-thirds of total weight loss occurred in the first 9 months, with the remaining third occurring between months 9-16. This is consistent with the body reaching a new energy equilibrium.
Real-World Results vs. Clinical Trials
Real-world data from large database studies suggests that average weight loss in clinical practice may be somewhat lower than trial data, typically 10-13% over 12 months. This gap is attributed to several factors: less structured follow-up than clinical trials, variable adherence, inconsistent medication supply, and differences in patient populations.
However, real-world studies also show a wider range of outcomes. Some patients achieve 20-25% weight loss while others lose less than 5%. Factors associated with better outcomes include higher starting BMI, consistent medication adherence, concurrent lifestyle modifications, and engagement with healthcare providers.
Factors That Influence Results
Several factors predict better or worse weight loss outcomes on semaglutide. Positive predictors include higher baseline BMI, early appetite suppression response (within first 4 weeks), adherence to the full titration schedule, concurrent high-protein diet (at least 1g per kg of lean body mass daily), and regular physical activity (especially resistance training to preserve lean mass).
Negative predictors include history of multiple failed weight loss attempts with medications, certain metabolic conditions, poor medication adherence or frequent dose interruptions, and lack of dietary modifications. Genetics also play a role, as GLP-1 receptor variants may influence individual response.
Maintaining Results Long-Term
The STEP 4 trial demonstrated that patients who discontinued semaglutide after 20 weeks of treatment regained approximately two-thirds of their lost weight over the following 48 weeks. This underscores that semaglutide treats obesity as a chronic condition requiring ongoing management.
Strategies for maintaining results include continued treatment at the lowest effective dose, structured lifestyle modifications that can be sustained independently, regular monitoring with healthcare providers, and psychological support for the behavioral aspects of weight management. Some patients successfully transition to lower maintenance doses while preserving most of their weight loss.
Frequently Asked Questions
How much weight can I expect to lose on semaglutide?
Clinical trials show an average of about 15% body weight loss over 68 weeks. For a 250-pound person, that's approximately 37 pounds. Individual results vary widely, with some losing 20%+ and others less than 5%.
When do you start losing weight on semaglutide?
Most patients notice the scale beginning to move within the first 4-6 weeks, with more significant weight loss starting around months 2-3 as doses increase. The fastest rate of loss typically occurs between months 3-9.
Does semaglutide work for everyone?
No. Approximately 14% of patients in the STEP 1 trial did not achieve 5% weight loss. Non-response can be related to genetics, metabolic factors, adherence issues, or other individual characteristics. If semaglutide isn't working after 3-4 months at therapeutic doses, discuss alternatives with your provider.
Is semaglutide weight loss permanent?
Weight loss requires ongoing treatment to maintain. The STEP 4 trial showed significant weight regain after discontinuation. Many providers recommend long-term or indefinite treatment, similar to how blood pressure or cholesterol medications are managed.
Find providers with proven weight loss outcomes
Compare pricing, reviews, and availability across 18,000+ GLP-1 providers nationwide.
Search Providers →Explore all Semaglutide topics
Cost guides, side effect management, dosing information, insurance coverage, and more — all backed by clinical data.